Biotech stocks jump after Moderna, Merck's melanoma vaccine succeeds in large trial
MRNA•Biotech stocks rise after melanoma vaccine trial success
** Shares of biotech cos rise premarket after Moderna's MRNA.O melanoma vaccine with Merck MRK.N succeeds in large trial
** U.S.-listed shares of BioNTech BNTX.O climbs ~16%, Novavax NVAX.O rises 7.1%, Virax Biolabs Group VRAX.O zooms 40% to $3.83
** Moderna soars 96%, while Merck climbs 6.9%
** Nasdaq biotech index .NBI is up nearly 22% YTD compared with 12.4% gain in the S&P 500 .SPX
